NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic Efficacy in Initial Animal Trials
"We were very pleased with the rapid response to treatment, and we had the opportunity to observe the excellent clinical response ourselves," said Eugene Seymour, MD, MPH, CEO of the Company. "The clinical results we observed are far superior to any data reported in the literature," said Anil R. Diwan, PhD, President of the Company.
The EKC study which is designed with a duration of four weeks, is currently in progress at a major medical center. Analysis of biological samples is expected to take several weeks following the completion of the study. The Company plans to make preliminary results available publicly as they are obtained.
There are approximately 5 million cases annually of this disease in the US, Europe and Japan. No adequate treatment exists at present. The infection causes severe pain, blurriness of vision and occasional blindness. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the Company projects the market for EKC and viral conjunctivitis may be several billion dollars annually.
The Company has now shown that two of its broad-spectrum nanoviricide drug candidates have excellent efficacies against substantially different virus types. We have now shown these nanoviricides to be very effective against certain non-enveloped viruses such as the EKC-causing adenovirus. Previously we have shown them to be highly effective against common influenza, bird flu (H5N1), rabies, and Ebola virus.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
Amanda Schuon, 310-550-7200
Posted: May 2008